AnnMHakeMDFAAN(She/Her)
Neurology • Indianapolis, INHeadache, Movement Disorder, Neurodegenerative, Dementia & Geriatrics
Executive Director, Eli Lilly and Company. Associate Professor of Clinical Neurology, Indiana University School of Medicine.
Dr. Hake is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Lilly Corporate Center
Indianapolis, IN 46285Phone+1 317-277-7278
Summary
- I am a board-certified Neurologist, fellowship trained in Neurodegenerative diseases. I am the physician member of the Digital Health R&D team, and the Vice Chair of the Bioethics Committee at Eli Lilly and Company. I previously was an Associate Professor of Clinical Neurology at Indiana University, where I continue to see patients twice monthly and serve on the IRB.
Education & Training
Indiana UniversityMasters Certificate, Medical Informatics, 2010 - 2011
Indiana University School of MedicineFellowship, Neurodegenerative Diseases, 1997 - 1999
Brown UniversityChief Residency, Neurology, 1992 - 1993- Brown UniversityResidency, Neurology, 1990 - 1993
Creighton University School of Medicine (Omaha)Internship, Internal Medicine, 1989 - 1990- Creighton University School of MedicineClass of 1989
Certifications & Licensure
IN State Medical License 1993 - 2025- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Comparative Research of Alzheimer's Disease Drugs Start of enrollment: 2011 Apr 01
Publications & Presentations
PubMed
- 33 citationsHigher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegenerationNicolai Franzmeier, M. Suárez-Calvet, Lukas Frontzkowski, Annah M. Moore, Timothy J. Hohman
Molecular Neurodegeneration. 2020-10-08 - 649 citationsTrial of Solanezumab for Mild Dementia Due to Alzheimer’s DiseaseLawrence S. Honig, Bruno Vellas, Michael M Woodward, Mercè Boada, Roger Bullock
The New England Journal of Medicine. 2018-01-24 - 29 citationsPredicting missing biomarker data in a longitudinal study of Alzheimer diseaseRaymond Y. Lo, William J. Jagust, Paul S. Aisen, Clifford R. Jack, Arthur W. Toga
Neurology. 2012-05-01
Other
- Clinical features and diagnosis of dementia with Lewy bodiesHake AM, Farlow MR
http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-dementia-with-lewy-bodies
UpToDate, Wolters Kluwer Health - 2013-02-06 - Epidemiology, pathology, and pathogenesis of dementia with Lewy bodiesHake AM, Farlow MR
http://www.uptodate.com/contents/epidemiology-pathology-and-pathogenesis-of-dementia-with-lewy-bodie
UpToDate, Wolters Kluwer Health - 2012-11-29 - Prognosis and treatment of dementia with Lewy bodiesHake AM, Farlow MR
http://www.uptodate.com/contents/prognosis-and-treatment-of-dementia-with-lewy-bodies
UpToDate, Wolters Kluwer Health - 2013-02-06
Industry Relationships
- Employee, Eli Lilly and Co.Full-time employeeDisclosure: Salary, stock2011 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
